APOA1 and Alzheimer disease: In vivo animal models of AD have further validated the beneficial effects of elevated circulating ApoAI, including a reduction in cerebral Aβ deposition, attenuation of neuroinflammation, and inhibition of the aberrant activation of astrocytes and microglia [30, 31, 32].